[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608658":3},{"organization":4,"outcomesModule":7,"designInfo":31,"detailedDescription":11,"studyPopulation":11,"armGroups":37,"interventions":43,"overallOfficials":51,"centralContacts":55,"locations":63,"responsibleParty":110,"collaborators":11,"id":112,"slug":11,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":11,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":119,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":11,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":66,"whyStopped":11,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},{"fullName":5,"class":6},"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Geometric mean ratio for the area under the concentration-time curve from time zero to 12 hours post morning dose (AUC(0-12))",null,"Up to Day 17",[14,17,19,21,23,25,27,29],{"measure":15,"description":11,"timeFrame":16},"Number of participants with Adverse Events (AEs)","Up to 28 days post last dose",{"measure":18,"description":11,"timeFrame":16},"Number of participants with Serious Adverse Events (SAEs)",{"measure":20,"description":11,"timeFrame":16},"Number of participants with physical examination abnormalities",{"measure":22,"description":11,"timeFrame":16},"Number of participants with vital sign abnormalities",{"measure":24,"description":11,"timeFrame":16},"Number of participants with electrocardiogram (ECG) abnormalities",{"measure":26,"description":11,"timeFrame":16},"Number of participants with clinical laboratory test abnormalities",{"measure":28,"description":11,"timeFrame":16},"Columbia-Suicide Severity Rating Scale (C-SSRS)",{"measure":30,"description":11,"timeFrame":16},"Number of participants with AEs of Special Interest (AESIs)",{"allocation":32,"interventionModel":33,"interventionModelDescription":11,"primaryPurpose":34,"observationalModel":11,"timePerspective":11,"maskingInfo":35},"NA","PARALLEL","TREATMENT",{"masking":36,"maskingDescription":11,"whoMasked":11},"NONE",[38],{"label":39,"type":40,"description":11,"interventionNames":41},"KarXT","EXPERIMENTAL",[42],"Drug: Xanomeline\u002F Trospium Chloride",[44],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":49},"DRUG","Xanomeline\u002F Trospium Chloride","Specified dose on specified days",[39],[50,39],"BMS-986510",[52],{"name":53,"affiliation":53,"role":54},"Bristol-Myers Squibb","STUDY_DIRECTOR",[56,61],{"name":57,"role":58,"phone":59,"phoneExt":11,"email":60},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":62,"role":58,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain the NCT# and Site #.",[64,82,96],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"Anaheim Clinical Trials","RECRUITING","Anaheim","California","92801","United States","US",{"type":73,"coordinates":74},"Point",[75,76],-117.9145,33.83529,{"lat":76,"lon":75},[79],{"name":80,"role":58,"phone":81,"phoneExt":11,"email":11},"Peter Winkle, Site 0003","949-295-7809",{"facility":83,"status":66,"city":84,"state":85,"zip":86,"country":70,"countryCode":71,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"ICON - Lenexa","Lenexa","Kansas","66219-9746",{"type":73,"coordinates":88},[89,90],-94.73357,38.95362,{"lat":90,"lon":89},[93],{"name":94,"role":58,"phone":95,"phoneExt":11,"email":11},"Patrick Yao, Site 0002","913-410-2674",{"facility":97,"status":66,"city":98,"state":99,"zip":100,"country":70,"countryCode":71,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"ICON Development Solutions","San Antonio","Texas","78209",{"type":73,"coordinates":102},[103,104],-98.49363,29.42412,{"lat":104,"lon":103},[107],{"name":108,"role":58,"phone":109,"phoneExt":11,"email":11},"Cassandra Key, Site 0001","210-283-4552",{"type":111,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100608658",false,"NCT07204418","A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants","A Phase 1, 4-part, Open-label Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants","Inclusion Criteria:\n\n* Participant must be healthy male and female (INOCBP) participants as determined by no clinically significant deviation from normal in medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs (VS), and clinical laboratory determinations.\n* Participant must be a normal\u002Fextensive, intermediate, poor, or ultrarapid CYP2D6 metabolizer.\n* Participant must have body mass index (BMI) of 18.0 to 32.0 kg\u002Fm2, inclusive.\n\nExclusion Criteria:\n\n* Participants must not have evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, 12-lead ECG, or clinical laboratory determinations beyond what is consistent with the target population reference ranges.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.",true,"ALL","18 Years","65 Years",{"count":123,"type":124},56,"ESTIMATED","INTERVENTIONAL",[127],"PHASE1","The purpose of this study is to evaluate the pharmacokinetics (PK) of xanomeline following administration of KarXT in CYP2D6 normal\u002Fextensive, intermediate, poor, and ultrarapid metabolizers.",[130],"Healthy Volunteers",[132,133,50,39,134,135],"Healthy volunteer","Pharmacokinetics","Cobenfy","CYP2D6","2026-02-17",{"date":138,"type":139},"2026-02-19","ACTUAL",{"date":141,"type":139},"2025-10-13",{"date":143,"type":124},"2026-12-03",{"name":5,"class":6},3]